Disorders of haem biosynthesis

Inborn Metabolic Diseases: Diagnosis and Treatment

Volumn , Issue , 2012, Pages 519-532

  Marquez Louren Ç O, Charles ^a   Lee, Chul ^b   Anderson, Karl E ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84956685983     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-15720-2_37     Document Type: Chapter

References (71)

1. Granick S (1966) The induction in vitro of the synthesis of d-aminolevulinic acid synthetase in chemical porphyria: a response to certain drugs, sex hormones, and foreign chemicals. J Biol Chem 241:1359-137
2. Anderson KE, Freddara U, Kappas A (1982) Induction of hepatic cytochrome P-450 by natural steroids: relationships to the induction of d-aminolevulinate synthase and porphyrin accumulation in the avian embryo. Arch Biochem Biophys 217:597-608
3. Harigae H, Furuyama K (2010) Hereditary sideroblastic anemia: pathophysiology and gene mutations. Int J Hematol 92:425-431
4. Bekri S, May A, Cotter PD et al. (2003) A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia. Blood 102:698-704
5. Cazzola M, May A, Bergamaschi G et al. (2000) Familial-skewed Xchromosome inactivation as a predisposing factor for late-onset Xlinked sideroblastic anemia in carrier females. Blood 96:4363-4365
6. Cazzola M, May A, Bergamaschi G et al. (2002) Absent phenotypic expression of X-linked sideroblastic anemia in one of 2 brothers with a novel ALAS2 mutation. Blood 100:4236-4238
7. Puy H, Gouya L, Deybach JC (2010) Porphyrias. Lancet 375:924- 937.9.
8. Sarkany RP (2008) Making sense of the porphyrias. Photodermatol Photoimmunol Photomed 24:102-108
9. Anderson KE (2003) The porphyrias. In: Zakim D, Boyer T (eds) Hepatology, chap 11. Saunders, Philadelphia, pp 291-346
10. Anderson KE, Bloomer JR, Bonkovsky HL et al. (2005) Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 142:439-450
11. Poh-Fitzpatrick MB, Lamola AA (1976) Direct spectrophotometry of diluted erythrocytes and plasma: a rapid diagnostic method in primary and secondary porphyrinemias. J Lab Clin Med 87:362-370
12. Poh-Fitzpatrick MB (1980) A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol 116:543-547
13. Akagi R, Kato N, Inoue R et al. 2006 d-Aminolevulinate dehydratase (ALAD) porphyria: The first case in North America with two novel ALAD mutations. Mol Genet Metab 87:329-336
14. Inoue R, Akagi R (2008) Co-synthesis of human delta-aminolevulinate dehydratase (ALAD) mutants with the wild-type enzyme in cell-free system – critical importance of conformation on enzyme activity. J Clin Biochem Nutr 43:143-153
15. Shimizu Y, Ida S, Naruto H, Urata G (1978) Excretion of porphyrins in urine and bile after the administration of delta-aminolevulinic acid. J Lab Clin Med 92:795-802
16. Pischik E, Kauppinen R (2009) Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-grand) 55:72-83
17. Maramattom BV, Zaldivar RA, Glynn SM, Eggers SD, Wijdicks EF (2005) Acute intermittent porphyria presenting as a diffuse encephalopathy. Ann Neurol 57:581-584
18. Sardh E, Andersson DE, Henrichson A, Harper P (2009) Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-grand) 55:66-71
19. Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 71:1-13
20. Andant C, Puy H, Bogard C et al. (2000) Faivre J, Soule JC, Nordmann Y, Deybach JC Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 32:933-939
21. Human Gene Mutation Database (www.hgmd.org)
22. Solis C, Martinez-Bermejo A, Naidich TP et al. (2004) Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. Arch Neurol 61:1764-1770
23. Deacon AC, Peters TJ (1998) Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem 35:726-732
24. Whatley SD, Mason NG, Woolf JR et al. (2009) Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem 55:1406-1414
25. Tenhunen R, Mustajoki P (1998) Acute porphyria: treatment with heme. Semin Liver Dis 18:53-55
26. Bonkovsky HL, Healey JF, Lourie AN, Gerron GG (1991) Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol 86:1050-1056
27. Hahn M, Gildemeister OS, Krauss GL et al. (1997) Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria. Neurology 49:97-106
28. Anderson KE (2003) Approaches to treatment and prevention of human porphyrias. In: Kadish KM, Smith K, Guilard R (eds) Porphyrin handbook, part II, chap 94, vol 14. Academic Press, San Diego, pp 247-284
29. Barone GW, Gurley BJ, Anderson KE et al. (2001) The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria. J Clin Pharmacol 41:113-115
30. Wahlin S, Harper P, Sardh E et al. (2010) Combined liver and kidney transplantation in acute intermittent porphyria. Transplant Int 23:e18-21
31. Seth AK, Badminton MN, Mirza D et al. (2007) Liver transplantation for porphyria: who, when, and how? Liver Transplant 13:1219-1227
32. Anderson KE, Spitz IM, Bardin CW, Kappas A (1990) A GnRH analogue prevents cyclical attacks of porphyria. Arch Intern Med 150:1469-1474
33. Verstraeten L, Regemorter v N, Pardou A et al. (1993) Biochemical diagnosis of a fatal case of Gunther’s disease in a newborn with hydrops-fetalis. Eur J Clin Chem Clin Biochem 31:121-128
34. Sassa S, Akagi R, Nishitani C et al. (2002) Late-onset porphyrias: what are they? Cell Mol Biol (Noisy-le-grand) 48:97-101
35. Ged C, Moreau-Gaudry F, Richard E et al. (2009) Congenital erythropoietic porphyria: mutation update and correlations between genotype and phenotype. Cell Mol Biol (Noisy-le-grand) 55:53-60
36. Phillips JD, Steensma DP, Pulsipher MA et al. (2007) Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood 109:2618-2621
37. Poh-Fitzpatrick MB, Piomelli S, Seaman C, Skolnick LM (1988) Congenital erythropoietic porphyria: complete suppression of symptoms by long-term high-level transfusion with deferoxam ine infusion iron rescue. In: Orfanos CE, Stadler R, Gollnick H (eds) Dermatology in five continents. Springer, Berlin Heidelberg New York, pp 876-879
38. Guarini L, Piomelli S, Poh-Fitzpatrick MB (1994) Hydroxyurea in congenital erythropoietic porphyria (letter). N Engl J Med 330:1091-1092
39. Fritsch C, Lang K, Bolsen K et al. (1998) Congenital erythropoietic porphyria. Skin Pharmacol Appl Skin Physiol 11:347-357
40. Faraci M, Morreale G, Boeri E et al. (2008) Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria. Pediatr Transplant 12:117-120
41. Zix-Kieffer I, Langer B, Eyer D et al. (1996) Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther’s disease). Bone Marrow Transplant 18:217-220
42. Geronimi F, Richard E, Lamrissi-Garcia I et al. (2003) Lentivirusmediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells. J Mol Med 81:310-320
43. Elder GH (2003) Porphyria cutanea tarda and related disorders. In: Kadish KM, Smith K, Guilard R (eds) Porphyrin handbook, Part II, vol 14, chap 88. Academic Press, San Diego, pp 67-92
44. Jalil S, Grady JJ, Lee C, Anderson KE (2010) Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol 8:297-302
45. Phillips JD, Bergonia HA, Reilly CA et al. (2007) A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A 104:5079-5084
46. Egger NG, Goeger DE, Anderson KE (1996) Effects of chloroquine in hematoporphyrin-treated animals. Chem Biol Interact 102:69-78
47. Phillips JD, Whitby FG, Stadtmueller BM et al. (2007) Two novel uroporphyrinogen decarboxylase (URO-D) mutations causing hepatoerythropoietic porphyria (HEP). Transl Res 149:85-91
48. Armstrong DK, Sharpe PC, Chambers CR et al. (2004) Hepatoerythropoietic porphyria: a missense mutation in the UROD gene is associated with mild disease and an unusual porphyrin excretion pattern. Br J Dermatol 151:920-923
49. Meissner P, Hift RJ, Corrigall A (2003) Variegate porphyria. In: Kadish KM, Smith K, Guilard R (eds) Porphyrin handbook, part II, vol 14, chap 89. Academic Press, San Diego, pp 93-120
50. Meissner P, Adams P, Kirsch R (1993) Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria. J Clin Invest 91:1436-1444
51. Poh-Fitzpatrick MB (1980) A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol 116:543-547
52. Poh-Fitzpatrick MB, Lamola AA (1976) Direct spectrofluorometry of diluted erythrocytes and plasma: a rapid diagnostic method in primary and secondary porphyrinemias. J Lab Clin Med 87:362-370
53. Da Silva V, Simonin S, Deybach JC et al. (1995) Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. Clin Chim Acta 238:163-168
54. Long C, Smyth SJ, Woolf J et al. (1993) Detection of latent variegate porphyria by fluorescence emission spectroscopy of plasma. Br J Dermatol 129:9-13
55. Holme SA, Worwood M, Anstey AV et al. (2007) Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 110:4108-4110
56. Cox TM (2003) Protoporphyria. In: Kadish KM, Smith K, Guilard R (eds) Porphyrin handbook, part II, vol 14, chap 90. Academic Press, San Diego, pp 121-149
57. Holme SA, Anstey AV, Finlay AY et al. (2006) Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 155:574-581
58. Jong CT, Finlay AY, Pearse AD et al. (2008) The quality of life of 790 patients with photodermatoses. Br J Dermatol 159:192-197
59. Muley SA, Midani HA, Rank JM et al. (1998) Neuropathy in erythropoietic protoporphyrias. Neurology 51:262-265
60. Whatley SD, Ducamp S, Gouya L et al. (2008) C-Terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 83:408-414
61. Whatley SD, Mason NG, Holme SA et al. (2010) Molecular epidemiology of erythropoietic protoporphyria in the United Kingdom. Br J Dermatol 162:642-646
62. Went LN, Klasen EC (1984) Genetic aspects of erythropoietic protoporphyria. Ann Hum Genet 48:105-117
63. Gouya L, Puy H, Robreau AM, Bourgeois M et al. (2002) The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 30:27-28
64. Holme SA, Whatley SD, Roberts AG et al. (2009) Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. J Invest Dermatol 129:599-605
65. Goodwin RG, Kell WJ, Laidler P et al. (2006) Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells. Blood 107:60-62
66. Harms J, Lautenschlager S, Minder CE, Minder EI (2009) An alphamelanocyte- stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 360:306-307
67. Harms JH, Lautenschlager S, Minder CE, Minder EI (2009) Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 85:1434-1439
68. Minder EI, Schneider-Yin X, Steurer J, Bachmann LM (2009) A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 55:84-97
69. Do KD, Banner BF, Katz E et al. (2002) Benefits of chronic plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria after orthotopic liver transplantation. Transplantation 73:469-472
70. Rand EB, Bunin N, Cochran W et al. (2006) Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 118:e1896-1899
71. Wahlin S, Harper P (2010) The role for BMT in erythropoietic protoporphyria. Bone Marrow Transplant 45:393-394